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We report the case of a patient with Rheumatoid Arthritis [RA] presenting with clinical-pathological and radiological
features of Pulmonary Lymphomatoid Granulomatosis (PLG). This is a rare lung disorder characterized by multiple
nodular lesions with lymphocytic invasion of vascular walls. We present one such case of PLG secondary to Methotrexate
and Azathioprine therapy, who was successfully treated with Steroids and Rituximab. We wish to highlight the importance
of lung biopsy in the diagnosis and the use of rituximab as a treatment modality for RA as well as PLG.
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We report the case of a patient with Rheumatoid Arthritis
[RA] presenting with clinical-pathological and radiological
features of Pulmonary Lymphomatoid Granulomatosis
(PLG). This is a rare lung disorder characterized by
multiple nodular lesions with lymphocytic invasion of
vascular walls. We present one such case of PLG sec-
ondary to Methotrexate and Azathioprine therapy, who
was successfully treated with Steroids and Rituximab.
We wish to highlight the importance of lung biopsy in
the diagnosis and the use of rituximab as a treatment
modality for RA as well as PLG.Case report
A 60 year old lady with anti-CCP and sero-positive
rheumatoid arthritis [RA] on methotrexate (MTX,
20 mg once weekly), hydroxycholroquine (HXQ, 200 mg
twice daily), azathioprine (AZA, 50 mg twice daily), pre-
sented with a history of weight loss (2 stone in 6 months),
poor appetite for 5 months, non-productive cough and
non exertional shortness of breath of few days duration.
Examination was unremarkable except for mouth ulcers,
an erythematous rash with irregular borders above the* Correspondence: rohit.peshin@gov.im
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White cell count was elevated along with a predominantly
raised neutrophil count, and CRP was elevated too. Bio-
chemical profile was unremarkable.
Chest x-ray revealed increased coarse, linear shadowing
in the mid- and lower zones, prominent hila, bilateral
Kerley B lines, and a pleural reaction on the left. Nodular
shadows were present bilaterally, the largest measuring
18 mm.
Methotrexate and Azathioprine were discontinued. As
concerns were raised about methotrexate lung disease,
Folinic acid rescue was instituted and broad spectrum
antibiotic cover with IV levofloxacin and oral clarithro-
mycin therapy was commenced.
CT scan revealed mediastinal (complex confluent
subcarinal lymph node mass measuring 5.6 cm), aorto-
pulmonary, paratracheal, right tracheobronchial, axillary,
upper abdominal (1.5 cm), external ileac and right inguinal
lymphadenopathy (largest 10.7 mm). There was widespread
reticulonodular shadowing, subpleural consolidation and
congestion of interlobular lymphatics. A small right pleural
effusion and little pleural thickening/pleural reaction
was reported in dependent parts of the left lower lobe
(Figure 1).an Open Access article distributed under the terms of the Creative Commons
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roperly credited.
Figure 1 CT scan chest.
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62% of predicted), with no evidence of restrictive venti-
latory defect.
Our Differential included lymphoma, sarcoidosis,
Wegener’s, pulmonary fibrosis and malignancy.
Lung biopsy conclusively diagnosed Pulmonary Lympho-
matoid Granulomatosis [PLG]. EBV PCR was negative.
An opinion was sought from the haematologists who
confirmed the diagnosis, malignancy was ruled out, and
as the lung picture had improved considerably with ste-
roids, it was agreed in an MDT setting that Rituximab
could be used to treat both the RA and PLG.
The patient improved significantly on steroids (Figure 1)
as well as rituximab infusions [dose 375 mg/m2 for
4 weeks]. The clinical response to treatment was very
good, and a post-treatment CT chest shows complete
resolution of lung changes.
The patient has been under surveillance for more than
a year now with no recurrence of joint symptoms, lung
complications or any extra articular complication. She
has a very good quality of life now. The rituximab ther-
apy really brought the disease as well as the PLG into
remission.Discussion
Pulmonary lymphomatoid granulomatosis (PLG) is a rare
lung disorder characterized by multiple nodular lesions
with lymphocytic invasion of vascular walls.
It is a nonspecific manifestation of conditions, in-
cluding autoimmunity, immunodeficiency, infection,
malignancy, lymphoproliferative disorder (Pittaluga et al.
2008; Katzenstein et al. 1979; Sordillo et al. 1982), can be
secondary to immunosuppressive medications such as
azathioprine, methotrexate, and imatinib where the dis-
order resolves after discontinuing medications (Katherine
Martin et al. 2009; Kameda et al. 2007; Pfistershammer et al.
2010; Pisani and DeRemee 1990). It generally presents
between 30 and 50 years, but any age group can be af-
fected (Koss et al. 1986). It has been associated with
Epstein-Barr virus infection in most cases (Pittaluga
et al. 2008). Immune defects may lead to an abnormal
host response to EBV infection (Pittaluga et al. 2008;
Jaffe and Wilson 1997).
Lungs are most commonly involved (>90 percent)
(Pittaluga et al. 2008) with or without skin and neuro-
logic involvement. The commonest presenting picture
includes fever, cough, rash/nodules, malaise, weight loss,
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(Katzenstein et al. 1979).
Laboratory investigations are nonspecific, but pulmon-
ary function test abnormalities can be characteristic
(Katzenstein et al. 1979).
Chest radiography typically reveals multiple poorly
defined nodules and/or masses in the mid- and lower-
lung zones with possible diffuse reticular abnormalities
(Jaffe and Wilson 1997; Katzenstein et al. 1979). Diagnosis
requires the histopathologic triad of polymorphic lymph-
oid infiltrates, transmural infiltration of arteries and veins
by lymphoid cells, and necrotic foci (not typical granu-
lomas) within the lymphoid infiltrates (Pittaluga et al.
2008).
The prognosis varies (Katzenstein et al. 1979) from re-
mission without treatment (Katzenstein et al. 1979; Jaffe
and Wilson 1997) to death within 2 years from malignant
lymphoma.
Treatment differs according to symptoms, use of
medication associated with PLG, extent of extrapul-
monary involvement, and histopathologic grade. Medi-
cation implicated in the disorder should be stopped
with repeated imaging over weeks to months (Pittaluga
et al. 2008).
To our knowledge after literature search, this is the
first case report of the use of Rituximab in treatment of
PLG which had developed as a complication of DMARD
therapy in a patient with RA.
Key message
Lymphatoid granulomatosis is a rare lymphoproliferative
disorder primarily affecting the lung, with variable clinical
outcome.
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